Clinical implications of PTEN loss in prostate cancer

Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer

(2017) Christophe Massard et al.   EUROPEAN JOURNAL OF CANCER

Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer

(2017) Andrew J. Armstrong et al.   EUROPEAN JOURNAL OF CANCER

Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy

(2017) Jeffrey J. Tosoian et al.   EUROPEAN UROLOGY

The Role of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Active Surveillance

(2017) Ting Martin Ma et al.   EUROPEAN UROLOGY

Low-risk Prostate Cancer: Identification, Management, and Outcomes

(2017) Marco Moschini et al.   EUROPEAN UROLOGY

DNA Repair in Prostate Cancer: Biology and Clinical Implications

(2017) Joaquin Mateo et al.   EUROPEAN UROLOGY

Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer

(2017) Alexander W Wyatt et al.   JNCI-Journal of the National Cancer Institute

PTEN Loss in Gleason Score 3 + 4 = 7 Prostate Biopsies is Associated with Nonorgan Confined Disease at Radical Prostatectomy

(2017) Liana B. Guedes et al.   JOURNAL OF UROLOGY

Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes PTEN/TP53- Deficient Prostate Cancer to Radiation

(2017) Anne L. van de Ven et al.   MOLECULAR CANCER THERAPEUTICS

Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer

(2017) Di Zhao et al.   NATURE

Managing high-grade prostatic intraepithelial neoplasia (HGPIN) and atypical glands on prostate biopsy

(2017) Jeffrey J. Tosoian et al.   Nature Reviews Urology

Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance

(2017) Sheng Yu Ku et al.   SCIENCE

Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations

(2017) Franklin W. Huang et al.   Cancer Discovery

Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer

(2017) Alexander W Wyatt et al.   JNCI-Journal of the National Cancer Institute

Differential Diagnosis of Intraductal Lesions of the Prostate

(2016) Sara E. Wobker et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer

(2016) Helen Chow et al.   CANCER

Premalignancy in Prostate Cancer: Rethinking What We Know

(2016) A. M. De Marzo et al.   Cancer Prevention Research

Mutational Landscape of Aggressive Prostate Tumors in African American Men

(2016) Karla J. Lindquist et al.   CANCER RESEARCH

A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score

(2016) Jonathan I. Epstein et al.   EUROPEAN UROLOGY

ERG and PTEN status of isolated high-grade PIN occurring in cystoprostatectomy specimens without invasive prostatic adenocarcinoma

(2016) Carlos L. Morais et al.   HUMAN PATHOLOGY

Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH

(2016) Tamara L Lotan et al.   MODERN PATHOLOGY

Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy

(2016) Kanerva Lahdensuo et al.   MODERN PATHOLOGY

PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance

(2016) Bruce J Trock et al.   MODERN PATHOLOGY

A PTENtial cause for the selectivity of oncolytic viruses?

(2016) Brian R Champion et al.   NATURE IMMUNOLOGY

Active surveillance for prostate cancer: a narrative review of clinical guidelines

(2016) Sophie M. Bruinsma et al.   Nature Reviews Urology

In prostate cancer needle biopsies, detections of PTEN loss by fluorescence in situ hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading

(2016) C. G. Picanço-Albuquerque et al.   VIRCHOWS ARCHIV

Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer

(2016) Alexander W. Wyatt et al.   JAMA Oncology

Utility of PTEN and ERG Immunostaining for Distinguishing High-grade PIN From Intraductal Carcinoma of the Prostate on Needle Biopsy

(2015) Carlos L. Morais et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients

(2015) Elizabeth A Punnoose et al.   BRITISH JOURNAL OF CANCER

Feedback Suppression of PI3Kα Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3Kβ

(2015) Sarit Schwartz et al.   CANCER CELL

Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer

(2015) Gretchen K. Hubbard et al.   CANCER RESEARCH

Integrative Clinical Genomics of Advanced Prostate Cancer

(2015) Dan Robinson et al.   CELL

The Molecular Taxonomy of Primary Prostate Cancer

(2015) Adam Abeshouse et al.   CELL

Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers

(2015) A. M. Aparicio et al.   CLINICAL CANCER RESEARCH

High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models

(2015) Rute B. Marques et al.   EUROPEAN UROLOGY

PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate

(2015) Roberta Ferraldeschi et al.   EUROPEAN UROLOGY

Heterogeneity of PTEN and ERG expression in prostate cancer on core needle biopsies: implications for cancer risk stratification and biomarker sampling

(2015) Rajal B. Shah et al.   HUMAN PATHOLOGY

Exploring Prostate Cancer Genome Reveals Simultaneous Losses of PTEN, FAS and PAPSS2 in Patients with PSA Recurrence after Radical Prostatectomy

(2015) Chinyere Ibeawuchi et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer

(2015) Jeffrey J. Tosoian et al.   JOURNAL OF CLINICAL ONCOLOGY

Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer

(2015) Stephen J Murphy et al.   MODERN PATHOLOGY

The evolutionary history of lethal metastatic prostate cancer

(2015) Gunes Gundem et al.   NATURE

The tumor suppressor PTEN has a critical role in antiviral innate immunity

(2015) Shun Li et al.   NATURE IMMUNOLOGY

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

(2015) Joaquin Mateo et al.   NEW ENGLAND JOURNAL OF MEDICINE

A multicenter study showsPTENdeletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer

(2015) Dean A. Troyer et al.   PROSTATE

Which, when and why? Rational use of tissue-based molecular testing in localized prostate cancer

(2015) A E Ross et al.   PROSTATE CANCER AND PROSTATIC DISEASES

STAT3 regulated ARF expression suppresses prostate cancer metastasis

(2015) Jan Pencik et al.   Nature Communications

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy

(2015) W. Peng et al.   Cancer Discovery

Focus on PTEN regulation

(2015) Miriam Bermúdez Brito   Frontiers in Oncology

Immune Infiltration and Prostate Cancer

(2015) Amy Strasner et al.   Frontiers in Oncology

Relevance and Therapeutic Possibility of PTEN-Long in Renal Cell Carcinoma

(2015) Hui Wang et al.   PLoS One

PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance

(2014) AndrewC Hsieh et al.   ASIAN JOURNAL OF ANDROLOGY

Mouse models of prostate cancer: picking the best model for the question

(2014) Magdalena M. Grabowska et al.   CANCER AND METASTASIS REVIEWS

Recurrent Prostate Cancer Genomic Alterations Predict Response to Brachytherapy Treatment

(2014) J. Fontugne et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Abstract 63: Incorporation of flanking probes reduces truncation losses for fluorescence in situ hybridization analysis of recurrent genomic deletions in tumor sections.

(2014) Maisa Yoshimoto et al.   CANCER RESEARCH

Evidence for Molecular Differences in Prostate Cancer between African American and Caucasian Men

(2014) F. Khani et al.   CLINICAL CANCER RESEARCH

Therapeutic Targeting of Cancers with Loss of PTEN Function

(2014) Lloye Dillon et al.   CURRENT DRUG TARGETS

TMPRSS2-ERG Fusions Are Strongly Linked to Young Patient Age in Low-grade Prostate Cancer

(2014) Stefan Steurer et al.   EUROPEAN UROLOGY

PTEN loss in biopsy tissue predicts poor clinical outcomes in prostate cancer

(2014) Prabhakar Mithal et al.   INTERNATIONAL JOURNAL OF UROLOGY

PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy

(2014) Tamara L Lotan et al.   MODERN PATHOLOGY

Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer

(2014) Antje Krohn et al.   MODERN PATHOLOGY

Vulnerabilities of PTEN-TP53-Deficient Prostate Cancers to Compound PARP-PI3K Inhibition

(2014) E. Gonzalez-Billalabeitia et al.   Cancer Discovery

Enhancing Chemotherapy Efficacy in Pten -Deficient Prostate Tumors by Activating the Senescence-Associated Antitumor Immunity

(2014) Alberto Toso et al.   Cell Reports

Analysis of circulating regulatory T cells (CD4+CD25+CD127−) after cryosurgery in prostate cancer

(2013) Tong-Guo Si et al.   ASIAN JOURNAL OF ANDROLOGY

Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer

(2013) J Cuzick et al.   BRITISH JOURNAL OF CANCER

Loss of PTEN Is Associated with Aggressive Behavior in ERG-Positive Prostate Cancer

(2013) K. A. Leinonen et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma

(2013) H.-L. Tan et al.   CLINICAL CANCER RESEARCH

Tracking the clonal origin of lethal prostate cancer

(2013) Michael C. Haffner et al.   JOURNAL OF CLINICAL INVESTIGATION

Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer ProgressionIn Vivo

(2013) Christian Thomas et al.   MOLECULAR CANCER THERAPEUTICS

ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss

(2013) Yu Chen et al.   NATURE MEDICINE

Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion

(2013) B Gumuskaya et al.   PROSTATE CANCER AND PROSTATIC DISEASES

A Secreted PTEN Phosphatase That Enters Cells to Alter Signaling and Survival

(2013) B. D. Hopkins et al.   SCIENCE

Nuclear PTEN Controls DNA Repair and Sensitivity to Genotoxic Stress

(2013) C. Bassi et al.   SCIENCE

Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate Cancer

(2012) Antje Krohn et al.   AMERICAN JOURNAL OF PATHOLOGY

PTENgenomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity

(2012) Khalil Choucair et al.   BMC CANCER

The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis

(2012) A. Pettersson et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity

(2012) Himisha Beltran et al.   EUROPEAN UROLOGY

Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer

(2012) Tarek A Bismar et al.   HISTOPATHOLOGY

Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer

(2012) Alison H M Reid et al.   MODERN PATHOLOGY

Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer

(2012) Alcides Chaux et al.   MODERN PATHOLOGY

Cytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from high-grade prostatic intraepithelial neoplasia

(2012) Tamara L Lotan et al.   MODERN PATHOLOGY

The mutational landscape of lethal castration-resistant prostate cancer

(2012) Catherine S. Grasso et al.   NATURE

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer

(2012) Christopher E Barbieri et al.   NATURE GENETICS

The functions and regulation of the PTEN tumour suppressor

(2012) Min Sup Song et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Cell Autonomous Role of PTEN in Regulating Castration-Resistant Prostate Cancer Growth

(2011) David J. Mulholland et al.   CANCER CELL

Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer

(2011) Brett S. Carver et al.   CANCER CELL

Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs

(2011) Yvonne Tay et al.   CELL

PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients

(2011) T. L. Lotan et al.   CLINICAL CANCER RESEARCH

PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications

(2011) Maisa Yoshimoto et al.   GENES CHROMOSOMES & CANCER

The genomic complexity of primary human prostate cancer

(2011) Michael F. Berger et al.   NATURE

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

(2011) Siyuan Zhang et al.   NATURE MEDICINE

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53

(2011) J Kim et al.   ONCOGENE

Non-genomic loss of PTEN function in cancer: not in my genes

(2011) Nick R. Leslie et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer

(2010) Tarek A. Bismar et al.   BJU INTERNATIONAL

Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer

(2010) A H M Reid et al.   BRITISH JOURNAL OF CANCER

Integrative Genomic Profiling of Human Prostate Cancer

(2010) Barry S. Taylor et al.   CANCER CELL

Oncolysis of Prostate Cancers Induced by Vesicular Stomatitis Virus in PTEN Knockout Mice

(2010) M. Moussavi et al.   CANCER RESEARCH

Intraductal Carcinoma of the Prostate Without Invasive Carcinoma on Needle Biopsy: Emphasis on Radical Prostatectomy Findings

(2010) Brian D. Robinson et al.   JOURNAL OF UROLOGY

Identification of the miR-106b 25 MicroRNA Cluster as a Proto-Oncogenic PTEN-Targeting Intron That Cooperates with Its Host Gene MCM7 in Transformation

(2010) L. Poliseno et al.   Science Signaling

Immunotherapy for Prostate Cancer: An Emerging Treatment Modality

(2010) Charles G. Drake   UROLOGIC CLINICS OF NORTH AMERICA

Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer

(2009) G. Attard et al.   CANCER RESEARCH

Simultaneous haploinsufficiency of Pten and Trp53 tumor suppressor genes accelerates tumorigenesis in a mouse model of prostate cancer

(2009) Suzana S. Couto et al.   DIFFERENTIATION

Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients

(2009) Philippe O. Gannon et al.   JOURNAL OF IMMUNOLOGICAL METHODS

PTENgenomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer

(2009) Kanishka Sircar et al.   JOURNAL OF PATHOLOGY

Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression

(2009) Bo Han et al.   MODERN PATHOLOGY

Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis

(2009) Jennifer C King et al.   NATURE GENETICS

Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate

(2009) Brett S Carver et al.   NATURE GENETICS

Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer

(2009) Wennuan Liu et al.   NATURE MEDICINE

Is PTEN loss associated with clinical outcome measures in human prostate cancer?

(2008) P McCall et al.   BRITISH JOURNAL OF CANCER

Tenets of PTEN Tumor Suppression

(2008) Leonardo Salmena et al.   CELL

Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome

(2008) Maisa Yoshimoto et al.   MODERN PATHOLOGY

Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis

(2008) Shidong Jia et al.   NATURE